These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 14647880)

  • 1. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study.
    Nielsen TF; Ravn P; Bagger YZ; Warming L; Christiansen C
    Osteoporos Int; 2004 Feb; 15(2):168-74. PubMed ID: 14647880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.
    Bhattoa HP; Bettembuk P; Balogh A; Szegedi G; Kiss E
    Osteoporos Int; 2004 May; 15(5):396-404. PubMed ID: 14676992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group.
    Delmas PD; Pornel B; Felsenberg D; Garnero P; Hardy P; Pilate C; Dain MP
    Bone; 1999 May; 24(5):517-23. PubMed ID: 10321913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial.
    Arrenbrecht S; Boermans AJ
    Osteoporos Int; 2002; 13(2):176-83. PubMed ID: 11908492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial.
    Prestwood KM; Kenny AM; Kleppinger A; Kulldorff M
    JAMA; 2003 Aug; 290(8):1042-8. PubMed ID: 12941676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Christiansen C
    Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
    Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
    Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
    J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
    Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
    Osteoporos Int; 2005 Apr; 16(4):372-9. PubMed ID: 15654581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.
    Weinstein RS; Parfitt AM; Marcus R; Greenwald M; Crans G; Muchmore DB
    Osteoporos Int; 2003 Oct; 14(10):814-22. PubMed ID: 14610642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
    Mok CC; Ying KY; To CH; Ho LY; Yu KL; Lee HK; Ma KM
    Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoporosis prevention clinical study program.
    Delmas P; Gimona A
    Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S39-45. PubMed ID: 8732473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women.
    Rubinacci A; Peruzzi E; Modena AB; Zanardi E; Andrei B; De Leo V; Pansini FS; Quebe-Fehling E; de Palacios PI
    Menopause; 2003; 10(3):241-9. PubMed ID: 12792297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.
    Cooper C; Stakkestad JA; Radowicki S; Hardy P; Pilate C; Dain MP; Delmas PD
    Osteoporos Int; 1999; 9(4):358-66. PubMed ID: 10550454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
    Gallagher JC; Fowler SE; Detter JR; Sherman SS
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.
    Zhu HM; Qin L; Garnero P; Genant HK; Zhang G; Dai K; Yao X; Gu G; Hao Y; Li Z; Zhao Y; Li W; Yang J; Zhao X; Shi D; Fuerst T; Lu Y; Li H; Zhang X; Li C; Zhao J; Wu Q; Zhao SJ
    Osteoporos Int; 2012 Apr; 23(4):1317-27. PubMed ID: 21505910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.